2015 Fiscal Year Final Research Report
Development of a novel therapy for melanoma that inhibits T cell suppressive molecules
| Project/Area Number |
25461687
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | メラノーマ / 免疫チェックポイント / TIGIT / CD155 / CD226 |
|---|
| Outline of Final Research Achievements |
Blocking antibody for T cell suppressive factors is an innovative melanoma therapy. In the previous study, we have identified 80 candidate molecules for novel T cell suppressive factors. Among them, we characterized some molecules that were useful as targets of melanoma therapy. We found that an inhibitory signal from CD155 on melanoma cells to TIGIT on T cells was selectively enhanced in the tumor environment. Also we have demonstrated that blocking antibody for TIGIT enhanced the anti-melanoma T cell response cooperatively with anti PD-1 antibody. Our data suggested the usefulness of anti-TIGIT blocking antibody as a novel melanoma therapy.
|
| Free Research Field |
癌免疫
|
